HTGM HTG MOLECULAR DIAGNOSTICS

HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TUCSON, Ariz., May 24, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that on May 22, 2019 the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 60,000 shares of common stock to five new employees.

Each stock option has an exercise price of $2.26 per share, HTG’s closing trading price on the grant date, and vests over approximately four years, with 1/4th of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares shall vesting in a series of 12 successive equal quarterly installments on the last day of each calendar quarter, commencing with the last day of the calendar quarter first occurring after the one-year anniversary of the applicable vesting commencement date, subject to the new employee's continued service relationship with HTG through the applicable vesting dates. Each stock option also has a 10-year term and is subject to the terms and conditions of HTG’s 2014 Equity Incentive Plan, as amended, and its standard form of agreement for inducement grants of nonstatutory stock options.

The stock options were granted as inducements material to the new employees entering into employment with HTG in accordance with Nasdaq Listing Rule 5635(c)(4).

About HTG:

HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. The company’s mission is to empower precision medicine at the local level.

Contact:

Ashley R. Robinson

LifeSci Advisors, LLC

Phone: (617) 535-7742

Email:

EN
24/05/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on HTG MOLECULAR DIAGNOSTICS

 PRESS RELEASE

HTG to Highlight the Advantages of its Drug Discovery Engine at the 20...

HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Convention TUCSON, Ariz., May 18, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biotechnology Innovation Organization (BIO) International Convention and will host in-person meetings during the remaining days of the June 5 – 8, 2023 event in Boston, MA. HTG is pioneering a proprietary platform-based approach ...

 PRESS RELEASE

HTG Highlights the Advantages of Its Drug Discovery Engine

HTG Highlights the Advantages of Its Drug Discovery Engine TUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG’s objective is to develop best-in-class molecules for the treatment of diseases, with the ability to apply its platform agnostical...

 PRESS RELEASE

HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provi...

HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights TUCSON, Ariz., May 10, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights. HTG has pioneered a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. At the center of this approach is the application of HTG...

 PRESS RELEASE

HTG Provides Update on Drug Discovery Partnering Initiative

HTG Provides Update on Drug Discovery Partnering Initiative TUCSON, Ariz., April 25, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today provided an update on partnering discussions for its drug discovery business unit. HTG has pioneered a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. At the center of this approach is the application of HTG’s proprietary RNA profiling technologies, function...

 PRESS RELEASE

HTG Announces Key First Quarter Milestone Achievements for Drug Discov...

HTG Announces Key First Quarter Milestone Achievements for Drug Discovery TUCSON, Ariz., April 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced the achievement of three significant drug discovery business milestones in the first quarter of 2023. As reported in January 2023, HTG filed a patent application on December 28, 2022, which included claims directed toward specific compounds, pharmaceutical compositions and methods of treating or preventing disease by administration ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch